Document is current
Any future updates will be listed below
-
Authors
Chapman, Fiona
Morrissey, Ruby
McDermott, Simon
Cahours, Xavier
Verron, Thomas
Taverner, Victoria
Stevenson, Matthew
Nahde, Thomas
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02907879 at ClinicalTrials.govDocuments that mention this clinical trial
Ultrasound Perfusion Imaging for the Detection of Cerebral Hypoperfusion After Aneurysmal Subarachnoid Hemorrhage
https://doi.org/10.1007/s12028-022-01460-z
Evaluation of high-nicotine oral products shows potential to reduce tobacco-related harm by offering satisfying alternatives
https://doi.org/10.1038/s41598-025-21812-x
- License Information
-
More Information
Article History
Received: 15 May 2025
Accepted: 24 September 2025
First Online: 3 October 2025
Declarations
:
: This study was funded by Imperial Brands PLC, manufacturers of the oral nicotine products used in this study. At the time of study, FC, RM, SM, XC, TV, VT, MS and TN were employees of Imperial Brands PLC or its subsidiaries, and XC, TV, MS, TN hold stocks/ shares in the company.
: The study was approved by the Swedish Ethical Review Authority (SERA), carried out in accordance with the ethical principles outlined in the Declaration of Helsinki, International Conference of Harmonisation (ICH)/ Good Clinical Practice (GCP), European Union Clinical Trials Directive and applicable local regulatory requirements.
: All subjects provided written informed consent prior to the study commencing.
